Pitt Shield

H-bonded organic frameworks as ultrasound-programmable delivery platform.

Authors: Wang W, Shi Y, Chai W, Tang KWK, Pyatnitskiy I, Xie Y, Liu X, He W, Jeong J, Hsieh JC, Lozano AR, Artman B, Shi X, Hoefer N, Shrestha B, Stern NB, Zhou W, McComb DW, Porter T, Henkelman G, Chen B, Wang H

The precise control of mechanochemical activation within deep tissues using non-invasive ultrasound holds profound implications for advancing our understanding of fundamental biomedical sciences and revolutionizing disease treatments<sup>1-4</sup>. However, a theory-guided mechanoresponsive materials system with well-defined ultrasound activation has yet to be explored<sup>5,6</sup>. Here we present the concept of using porous hydrogen-bonded organic frameworks (HOFs) as toolkits for focused ultrasound (FUS) programmably triggered drug activation to control specific cellular events in the deep brain, through on-demand scission of the supramolecular interactions. A theoretical model is developed to potentially visualize the mechanochemical scission and ultrasound mechanics, providing valuable guidelines for the rational design of mechanoresponsive materials to achieve programmable control. To demonstrate the practicality of this approach, we encapsulate the designer drug clozapine N-oxide (CNO) into the optimal HOF nanocrystals for FUS-gated release to activate engineered G-protein-coupled receptors in the ventral tegmental area (VTA) of mice and rats and hence achieve targeted neural circuit modulation even at depth 9 mm with a latency of seconds. This work demonstrates the capability of ultrasound to precisely control molecular interactions and develops ultrasound-programmable HOFs to non-invasively and spatiotemporally control cellular events, thereby facilitating the establishment of precise molecular therapeutic possibilities.

Introduction

Purpose Drug delivery WITHOUT BBB opening
Study Objective To develop and demonstrate porous hydrogen-bonded organic frameworks that enable theory-guided, focused ultrasound–programmable release of encapsulated drugs for noninvasive, spatiotemporal control of cellular activity in deep brain tissue.
Animal model / Human subject Mice and rats; strain: not reported; age: not reported; sex: not reported
Disease model Healthy
Targeted brain region(s) Ventral tegmental area
Cargo name and characteristics Clozapine N-oxide (CNO) — a small-molecule designer drug (DREADD agonist) encapsulated in HOF nanocrystals for focused ultrasound–gated release to activate engineered G-protein-coupled receptors in the brain.

Outcomes and Safety

Summary of Outcomes Focused ultrasound-triggered release of clozapine N-oxide from porous HOF nanocrystals activated engineered G-protein-coupled receptors in the ventral tegmental area of mice and rats, producing targeted neural circuit modulation. FUS gating was effective at depths up to 9 mm with latencies on the order of seconds.
Safety-related matter No safety concerns, adverse effects, toxicity, or side-effect assessments are mentioned in the provided excerpt.

Brain Region

Ultrasound Parameters

Ultrasound instrument Focused ultrasound transducer (Image Guided Therapy, Pessac, France)
FUS Frequency 1.5 MHz
FUS Pressure 1.4 Mpa
FUS Mode pulsed
Pulse duration 20 s
Duration of a single FUS session 20 s
Focal Characteristics Focal depth: 9 mm; Focal length: None; Aperture size: None

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search